NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

CompletedN/A

Sponsor: Alfasigma S.p.A.

Conditions: Rheumatoid Arthritis

Interventions: Filgotinib

Countries: France

An observational study to describe the effectiveness, safety, and patient-reported outcomes (PROs) in participants with moderate to severe active rheumatoid arthritis (RA) in France receiving filgotinib in real-world setting.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time.
* Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label.
* Participants must be willing and able to use an electronic device to complete the study PROs.
* Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study.

Exclusion Criteria:

* Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries.
* Female participant is pregnant or intending to become pregnant while taking filgotinib.

Locations (17)

Amiens, France
Amiens, France
Bobigny, France
Bordeaux, France
Cahors, France
Caluire-et-Cuire, France
Corbeil-Essonnes, France
Lille, France
Nice, France
Orléans, France
Paris, France
Paris, France
Reims, France
Rouen, France
Saint-Etienne, France
Toulouse, France
Tours, France